Novel approaches to treating SWI/SNF complex mutations in bladder cancer in the future might involve the utilisation of immune checkpoint inhibitors [17, 54], signalling pathway inhibitors [23, 58, 61], EZH2 inhibitors [24, 58, 60, 61], among others. Here, EZH2 is linked to urinary bladder cancer.